U.S., Aug. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07129759) titled 'Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency' on Aug. 05.
Brief Summary: This is a Multi-national Trial. The Goal of the Trial is to Offer Subjects Who Complete 12 Months in the LUM-201-10 Phase 3 Trial up to an Additional 36 Months of Treatment of LUM-201 While Evaluating Safety and Tolerability of LUM-201.
Study Start Date: Sept., 2026
Study Type: INTERVENTIONAL
Condition:
Growth Hormone Deficiency (GHD)
Intervention:
DRUG: LUM-201
1.6 mg/kg/day, administered orally once daily
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Lumos Pharma
Disclaimer: Curated by HT Syndicati...